UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2016

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Presentation to Accompany Evogene's Second Quarter 2016 Financial Results Conference Call.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 11, 2016

EVOGENE LTD. (Registrant)

By: /s/ Eyal Leibovitz Eyal Leibovitz Chief Financial Officer EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION

99.1 Presentation to Accompany Evogene's Second Quarter 2016 Financial Results Conference Call.

Validation Results and Update August 2016

Safe Harbor Statement

This resentation contains "forward-looking to future events, and we may from time to time make other statements, rearding our outlook or expectations for future financial or other matters regarding or affecting Evogene Itd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Form F-1, Anual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements atting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligation s required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information on this presentation or to publicly release the results of any statements that may be made to reflect future events or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the propers thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Introducing Evogene

. Located
- · HQ Rehovot, Israel
- · R&D site St. Louis, USA
" ~200 employees, 80% R&D
Listed TASE (2007); NYSE (2013)
Innovative discovery technology broadly applicable proprietary platform, combining cutting-edge computational capabilities with interdisciplinary biological expertise
Two R&D hubs for improving crop productivity
- · Crop enhancement yield, drought tolerance and fertilizer use efficiency
- · Crop protection insect resistance, disease and weeds
Collaborations with world-leading agriculture companies - Bayer, BASF, DuPont, Monsanto, Syngenta
Targeting 3 major markets
- · Seed traits ~\$37B1
- · Ag-Chemicals ~\$55B2
- · Ag-Biologicals ~\$4B3
1 Source: Phillips McDougall , 2016

Source: Phillips McDougall, 2015

Market overview & potential

		Yield & abiotic stress tolerance - recent results & updates

Subset of genes improved predicted trait attributes for yield - Further testing undertaken for these genes as well as additional previously discovered genes	MONSANTO

Evogene Discloses Positive Results in Yield Improvement Collaboration with Monsanto Utilizing Novel 'Trait-First' Methodology
February 23rd, 2016
Results, obtained for a set of Evogene discovered genes, in testing by its key collaborator, Monsanto, demonstrate potential to achieve yield enhancement in corn and soybean.
Rehovot, Israel - February 230, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries announced today positive results from the
testing of a set of the Company's discovered genes in corn and soybeans conducted this past season by its key collaborator, Monsanto. These are the
first results for genes discovered and tested pursuant to a 'Trait-First' methodology implemented in the frame of the parties' on-going, multi-year collaboration which focuses on yield enhancement and abiotic stress resistance.